Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to date, IBB has risen 18.2% versus SPY's 17.2% gain.
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
| XHAN Exchange | US Country |
The described company operates as an investment fund focused on tracking the performance of a specific underlying index. By investing at least 80% of its assets in the securities that comprise the index, the fund aims to mimic the index's returns and behavior closely. This strategy indicates a focus on providing investors with exposure to the components of a particular market or sector through the index it follows. However, it is noteworthy that the fund is characterized as non-diverse, which means it may concentrate its investments in a particular sector, company, or geographical area, potentially increasing the risk of volatility and loss due to lack of diversification.
The fund offers a targeted investment product that primarily focuses on securities from its underlying index, alongside additional financial instruments to potentially enhance returns and manage risks: